Biocon's Malaysian subsidiary surpassed 100 million insulin cartridges for Malaysia's MoH, serving 345,000 patients since 2016.

• Public-private partnership drives innovation and local talent development in Malaysia's biotech ecosystem.
• Over 345,000 patients benefited from affordable insulin access since the 2016 market entry.
• Achievement advances Malaysia's insulin self-sufficiency and diabetes care transformation.